Karo Bio has two clinical and four preclinical projects. In addition, Karo Bio runs several explorative activities on its way to drug discovery. Once in drug discovery Karo Bio will publically disclose new projects. 

Currently there is a focus on TR, GR and ER as drug discovery targets for the internal projects.

There is a potential for treatment of many important diseases by targeting these receptors. Besides, these receptors are well characterized which reduces the risk for unexpected findings.

With reference to TR, it is well known that TR is involved in lipid metabolism and energy expenditure which opens possibilities to treat dyslipidemia and obesity. Metabolic diseases are also targets regarding GR which is a key regulator of glucose metabolism. In this area, Karo Bio runs a project for treatment of type 2 diabetes. In the ER area Karo Bio is focusing on ER beta and depression since this receptor appears to play an important role for mood and cognitive function.                                                                       

Apart from internal projects Karo Bio collaborates with international pharmaceutical companies. The collaboration with Wyeth Pharmaceuticals targets the LXR receptor for treatment of atherosclerosis whereas the indication in the Merck collaboration is undisclosed.

The collaboration with Zydus Cadila targets the glucocorticoid receptor with the aim to develop novel compounds for treatment of inflammatory disorders.